Furthermore, KEAP1 mutations are associated with a specific T cell-inflamed gene-expression profile (GEP), an emerging biomarker predicting antitumor responses of immunotherapy targeting the PD-1 axis in various tumor types 95. The gene discussed is KEAP1; the disease is neoplasm.